PrefaceUS Renal Data System 2011 Annual Data Report
Section snippets
Acknowledgements
Suggested Citation: Collins AJ, Foley RN, Chavers B, et al: US Renal Data System 2011 Annual Data Report. Am J Kidney Dis. 2012;59(1)(suppl 1):e1-e420.
Publications based upon USRDS data reported here or supplied upon request must include this citation and the following notice: The data reported here have been supplied by the US Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or
References (0)
Cited by (230)
Latest advances in frailty in kidney transplantation: A narrative review
2024, Transplantation ReviewsChronic suppression of STIM1-mediated calcium signaling in Purkinje cells rescues the cerebellar pathology in spinocerebellar ataxia type 2
2023, Biochimica et Biophysica Acta - Molecular Cell ResearchThe association between long-term glycemic control and all-cause mortality is different among older versus younger patients with diabetes mellitus and maintenance hemodialysis treatment
2022, Diabetes Research and Clinical PracticeCitation Excerpt :Diabetes mellitus is associated with increased risk of chronic kidney disease (CKD) and further development to end-stage-renal-disease (ESRD) [1,2].
The Mortality Risk of Proton Pump Inhibitors in 1.9 Million US Seniors: An Extended Cox Survival Analysis
2022, Clinical Gastroenterology and HepatologyCitation Excerpt :About 60% and 40% of nursing home and hospital patients, respectively, are treated with PPIs for stress ulcer prevention30,31 and such hospitalizations can presage death. Roughly 30% of dialysis patients take PPIs for peptic symptoms and the prevention of gastrointestinal (GI) bleeding23 and dialysis itself carries a 50%, 3-year mortality rate.32 Patients taking anticoagulants or antiplatelet medications are another population who receive PPIs for upper GI protection,24,25 as do up to 80% of liver cirrhosis patients.33
Musculoskeletal disorders in hemodialysis patients: prevalence, clinical symptoms, and associated factors
2024, Journal of Nephropharmacology